



Viral Epidemiology Snapshot: March 27-April 2, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	639	159	24.9%
Flu B	639	2	0.3%
RSV	259	3	1.2%
CoV-2 PUI	746	20	2.7%
CoV-2 Surveillance	415	0	0.0%


Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	29
No Subtype	130
Pending subtype	0

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	257	21	8.2%
Coronavirus 229E	257	11	4.3%
Coronavirus HKU1	257	1	0.4%
Coronavirus NL63	257	7	2.7%
Coronavirus OC43	257	12	4.7%
Metapneumovirus	257	12	4.7%
Rhinovirus/Enterovirus	257	76	29.6%
Parainfluenza 1	257	0	0.0%
Parainfluenza 2	257	0	0.0%
Parainfluenza 3	257	6	2.3%
Parainfluenza 4	257	1	0.4%

Flu, RSV, & CoV-2 Trends



This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/20) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

CoV-2 Positivity Rate Trends

